Sutro Biopharma STRO 深 滬
已收盤 07-10 16:00:00 美东时间
29.73
-0.260
-0.87%
華盛通- 最 高30.13
- 今 開29.78
- 成交量 24.24万股
- 最 低 27.80
- 昨 收 29.99
- 總市值 4.93亿
- 52周最高 43.85
- 市盈率 靜 --
- 換手率 1.46%
- 52周最低 7.211
- 委 比 -69.14%
- 總股本 1657.04万
- 歷史最高 283.00
- 量 比 0.56
- 振 幅 7.77%
- 歷史最低 5.231
- 每 手 1
- 風險率 9.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc. announced that its management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on July 15, 2026, and the BTIG Virtual Biotechnology Conference on July 28, 2026. The company, focused on developing high-fidelity vaccines, is advancing several candidates, including VAX-31 and VAX-24 for pneumococcal disease prevention, VAX-A1 for Group A Strep, and VAX-GI for Shigella. Vaxcyte utilizes its XpressCF pla...
07-08 20:05
Aura Biosciences appoints Jeremy Bender to board of directors
Aura Biosciences appoints Jeremy Bender to board of directors Aura Biosciences appointed Jeremy Bender to its board of directors. Bender previously served as CEO and president of Day One Biopharmaceuticals, leading the approval and launch of OJEMDA. He also led Day One through its roughly $2.5 billi
07-08 19:04
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences appoints Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Bender, a biotech leader with experience in advancing therapies and commercialization, joins as the company prepares for potential regulatory approval of bel-sar for early choroidal melanoma. Aura aims to develop precision therapies preserving organ function, with bel-sar in late-stage development. Bender previously led Day One Biopharmaceuticals through its $2.5 b...
07-08 11:01
美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50
Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $50.
06-11 20:46
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56
Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overweight rating and announces Price Target of $56.
05-28 21:40
Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial results and issuing positive sales guidance. Other notable gainers and losers in pre-market trading include AMST, HAO, MTVA, ONCO, SDA, PIII, VRAX, PURR, BKKT, WOK, BTM, and UBXG.
05-19 16:47
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
HC Wainwright & Co. Maintains Buy on Sutro Biopharma, Raises Price Target to $50
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $28 to $50.
05-15 18:34
